Diversified Trust Co. Purchases 6,742 Shares of Insulet Corporation $PODD

Diversified Trust Co. grew its position in Insulet Corporation (NASDAQ:PODD) by 495.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,102 shares of the medical instruments supplier’s stock after buying an additional 6,742 shares during the period. Diversified Trust Co.’s holdings in Insulet were worth $2,303,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PODD. True Wealth Design LLC grew its stake in Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in shares of Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares during the period. Quent Capital LLC bought a new position in shares of Insulet during the 3rd quarter valued at about $49,000. Measured Wealth Private Client Group LLC bought a new position in shares of Insulet during the 3rd quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Insulet in the 2nd quarter valued at approximately $51,000.

Analysts Set New Price Targets

A number of research firms recently issued reports on PODD. Evercore set a $340.00 target price on Insulet in a research note on Thursday, February 19th. JPMorgan Chase & Co. cut their price target on shares of Insulet from $415.00 to $340.00 and set an “overweight” rating on the stock in a research note on Thursday, February 19th. Leerink Partners reduced their price target on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. Raymond James Financial lowered their price objective on shares of Insulet from $385.00 to $355.00 and set an “outperform” rating for the company in a research report on Thursday, February 19th. Finally, Oppenheimer dropped their price objective on shares of Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $354.24.

Insider Activity

In related news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.39% of the stock is currently owned by corporate insiders.

Insulet Price Performance

NASDAQ:PODD opened at $225.50 on Wednesday. Insulet Corporation has a 52-week low of $216.49 and a 52-week high of $354.88. The company has a market cap of $15.88 billion, a P/E ratio of 64.43, a P/E/G ratio of 1.36 and a beta of 1.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. The stock’s 50-day simple moving average is $250.03 and its 200 day simple moving average is $291.12.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. The firm had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 earnings per share. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.